IBSRELA Drug Patent Profile

When do Ibsrela patents expire, and what generic alternatives are available?

Ibsrela is a drug marketed by Ardelyx Inc and is included in one NDA. There are six patents protecting this drug.

This drug has forty-eight patent family members in twenty-two countries.

The generic ingredient in IBSRELA is tenapanor hydrochloride. One supplier is listed for this compound. Additional details are available on the tenapanor hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Ibsrela

Ibsrela was eligible for patent challenges on September 12, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 1, 2033. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for IBSRELA

International Patents:	48
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	39
Clinical Trials:	1
Drug Prices:	Drug price information for IBSRELA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IBSRELA
What excipients (inactive ingredients) are in IBSRELA?	IBSRELA excipients list
DailyMed Link:	IBSRELA at DailyMed

See drug prices for IBSRELA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IBSRELA

Constraining patent/regulatory exclusivity:

8,541,448

NDA:

211801

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IBSRELA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ardelyx	Phase 3

See all IBSRELA clinical trials

Pharmacology for IBSRELA

Drug Class	Sodium-Hydrogen Exchanger 3 Inhibitor
Mechanism of Action	Organic Anion Transporting Polypeptide 2B1 Inhibitors Sodium-Hydrogen Exchanger 3 Inhibitors

US Patents and Regulatory Information for IBSRELA

IBSRELA is protected by six US patents.

This potential generic entry date is based on patent 8,541,448.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes	9,006,281
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes	12,539,299		Y
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes	9,408,840
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes	8,969,377		Y	Y
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes	8,541,448		Y	Y
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes	12,016,856		Y	Y

International Patents for IBSRELA

When does loss-of-exclusivity occur for IBSRELA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

Norway

Poland

Portugal

San Marino

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IBSRELA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2748607
Spain	2657938
Spain	2657938
San Marino	T201800071
European Patent Office	3351248
South Korea	20110110287	COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

Market Dynamics and Financial Trajectory for IBSRELA

Last updated: February 20, 2026

What is the Current Market for IBSRELA?

IBSRELA (tenapanor) is a pharmaceutical approved by the FDA for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adult patients. Launched in late 2021, it targets a niche segment with limited therapeutics. In 2022, the global IBS community estimated the prevalence of IBS-D at approximately 10-15% of the adult population, with roughly 30 million potential US patients.

The drug’s market potential depends on two key factors: the size of diagnosed IBS-D patients and physician prescribing behavior. As of 2023, estimates suggest only 25-30% of IBS-D patients are diagnosed, limiting immediate market penetration.

How Does IBSRELA Fit Market Trends?

The shift toward targeted, mechanism-based therapies positions IBSRELA favorably. Its mechanism, a sodium/hydrogen exchanger 3 (NHE3) inhibitor, distinguishes it from traditional anti-diarrheal agents like loperamide or antispasmodics.

The broader gastrointestinal (GI) drug market is valued at about $9 billion annually (2022 estimates). IBS-specific treatments account for approximately $2 billion. IBSRELA's share depends heavily on physician acceptance and insurance coverage.

What Are the Regulatory Approvals and Reimbursement Landscape?

IBSRELA’s FDA approval followed positive phase 3 trial results demonstrating significant reduction in diarrhea frequency. Health authorities in Europe have not yet approved the drug, though filings are underway. Reimbursement status influences revenue; as of 2023, insurance coverage is common but varies regionally.

Medicare and commercial insurers tend to favor drugs with demonstrated real-world benefit and cost-effectiveness. Pricing in the US ranges around $5,000 per month, which affects patient access and market expansion.

What Is the Competitive Landscape?

Existing competitors include:

• Rifaximin (Xifaxan): Indicated for IBS-D. Annual US sales near $300 million (2022).

• Eluxadoline (Viberzi): Generated approximately $174 million in US sales (2022).

• Lubiprostone (Amitiza): A chloride channel activator, mainly for constipation but off-label use for certain IBS cases.

IBSRELA faces competition not just from drugs but from the broader management paradigm emphasizing diet, fiber intake, and psychological therapy. Its unique mechanism gives it an edge for patients refractory to existing therapy.

What Are the Sales Projections and Financial Trajectory?

Initial sales launched in late 2021 with an expected ramp-up in 2022-2024. Year-over-year growth predicted in the mid-final single digits initially, accelerating as prescription volume increases and insurance coverage expands.

Based on conservative estimates:

Year	US Sales (Estimated)	Global Sales (Projected)
2022	$45 million	$50 million
2023	$120 million	$130 million
2024	$250 million	$275 million

Revenue growth depends on physician adoption rates, patient access, and competitive responses. The international rollout may initially lag due to approval timelines.

What Are the Risks and Opportunities?

Risks:

• Limited diagnosis rate of IBS-D.
• Competition from established therapies and off-label use.
• Pricing pressures from payers.

Opportunities:

• Expanding indications, including other diarrhea-predominant GI disorders.
• Enhancing patient access through formulary negotiations.
• Conducting post-market studies to demonstrate long-term benefits.

Key Takeaways

• IBSRELA holds a niche position in the IBS-D treatment market, with room for expansion.
• Growth relies on increased diagnosis, physician awareness, and insurance coverage.
• The competitive landscape favors a differentiated mechanism, but sales hinge on market acceptance.
• Projected US sales reach $250 million by 2024, with international growth contingent on regulatory approvals.
• Market entry risks include low diagnosis rates and payer resistance, but the drug’s mechanism offers differentiation potential.

FAQs

1. How does IBSRELA compare to existing IBS-D treatments?
It targets a specific mechanism (NHE3 inhibition), offering a novel option for patients unresponsive to traditional anti-diarrheal drugs.

2. What are the main barriers to market growth for IBSRELA?
Low diagnosis rates, insurance reimbursement challenges, and competition from generic or off-label options.

3. What is the typical price point for IBSRELA?
Approximately $5,000 per month in the US, aligning with branded specialty GI therapy prices.

4. Are there ongoing clinical trials for additional indications?
Yes, trials are underway to evaluate IBSRELA’s use in other diarrhea-predominant GI conditions, potentially broadening usage.

5. When is global approval expected?
European filings are in progress, with approval expected within the next 12-24 months, depending on regulatory review timelines.

---

References

1. NIH National Institute of Digestive Diseases. (2022). IBS prevalence and treatment.
2. IQVIA. (2022). U.S. pharmaceutical sales data.
3. U.S. Food and Drug Administration. (2021). IBSRELA approval letter.
4. MarketResearch.com. (2022). Gastrointestinal therapeutics market report.
5. Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for GI drugs.